Celecoxib Treatment for Lung Cancer

This study is currently recruiting participants.

Verified by Department of Veterans Affairs, May 2007

Sponsored by:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs
ClinicalTrials.gov Identifier:	NCT00108186

Purpose

This proposal evaluates cyclooxygenase 2 (COX-2) inhibition as a means to decrease T regulatory cell activities and thus augment immune responses against lung cancer. The broad goal focuses on understanding how COX-2 expression regulates the malignant phenotype in non small cell lung cancer in an effort to foster an informed approach for the use of COX-2 inhibitors in prevention and therapy for lung cancer.

Condition	Intervention	Phase
Non-Small-Cell Lung Carcinoma	Drug: Celecoxib	Phase I

MedlinePlus related topics: Cancer Lung Cancer

Drug Information available for: Celecoxib 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Placebo Control, Crossover Assignment, Bio-availability Study
Official Title:	Celecoxib-Mediated Inhibition of T Regulatory Cells in Human Lung Cancer

Further study details as provided by Department of Veterans Affairs:

Study Start Date:	October 2004
Estimated Study Completion Date:	September 2009

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Pathologically confirmed and surgically resectable non small cell lung cancer and subjects must be ineligible for or refuse, neoadjuvant therapy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00108186

Locations

United States, California
VA Greater Los Angeles Healthcare System	Recruiting
Los Angeles, California, United States, 90073
Contact: Steven M. Dubinett, M.D. 310-478-3711 ext 41176 sdubinett@mednet.ucla.edu
Principal Investigator: Steven M. Dubinett, M.D.

Sponsors and Collaborators

Department of Veterans Affairs

More Information

Study ID Numbers:	ONCA-043-04S
Study First Received:	April 14, 2005
Last Updated:	May 15, 2007
ClinicalTrials.gov Identifier:	NCT00108186
Health Authority:	United States: Federal Government

Keywords provided by Department of Veterans Affairs:

lung cancer
cyclooxygenase 2
lymphocytes
theraputics
non small cell

Study placed in the following topic categories:

Thoracic Neoplasms
Non-small cell lung cancer
Celecoxib
Respiratory Tract Diseases
Lung Neoplasms

Lung Diseases
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Carcinoma

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Respiratory Tract Neoplasms
Neoplasms by Histologic Type
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Pharmacologic Actions
Neoplasms

Neoplasms by Site
Analgesics, Non-Narcotic
Sensory System Agents
Therapeutic Uses
Anti-Inflammatory Agents, Non-Steroidal
Analgesics
Peripheral Nervous System Agents
Antirheumatic Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 15, 2009